Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

The life sciences tools and services sector supports the research, development, and commercialization of biotechnology and pharmaceutical products. These companies offer a broad range of tools, from lab consumables and testing equipment to data analytics platforms and clinical trial support. There is recurring revenue potential from long-term contracts, high margins from specialized products, and the growing demand for precision medicine and data-driven insights. However, challenges include dependence on research and development budgets from large pharmaceutical companies and the boom and bust nature of smaller biotech companies. Looking forward, the life sciences tools and services sector is expected to benefit from strong tailwinds, including advancements in genomics and the rising focus on personalized medicine. Ongoing adoption of artificial intelligence in research and drug discovery, along with the growing need for regulatory compliance and data analytics, should provide longer-term demand support. However, headwinds such as the uncertainty around healthcare and research funding as well as pricing pressures from cost-conscious customers may feed into uncertainty in the sector.

The 21 life sciences tools & services stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 1.1% while next quarter’s revenue guidance was in line.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 14.6% since the latest earnings results.

Slowest Q4: PacBio (NASDAQ:PACB)

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

PacBio reported revenues of $39.22 million, down 32.8% year on year. This print fell short of analysts’ expectations by 1.8%. Overall, it was a disappointing quarter for the company with a miss of analysts’ EPS estimates.

"2024 was a challenging yet transformative year for PacBio, marked by the successful launch of new products, disciplined cost management, and strategic progress in our clinical strategy. Despite macroeconomic pressures, we have continued to innovate and expand accessibility to HiFi sequencing,” said Christian Henry, President and CEO of PacBio.

PacBio delivered the weakest performance against analyst estimates and slowest revenue growth of the whole group. The stock is down 16.3% since reporting and currently trades at $1.23.

Read our full report on PacBio here, it’s free.

Best Q4: Bio-Techne (NASDAQ:TECH)

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Bio-Techne reported revenues of $297 million, up 9% year on year, outperforming analysts’ expectations by 4.2%. The business had an exceptional quarter with a solid beat of analysts’ organic revenue estimates and a decent beat of analysts’ EPS estimates.

Bio-Techne scored the biggest analyst estimates beat among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 15.3% since reporting. It currently trades at $61.50.

Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it’s free.

Fortrea (NASDAQ:FTRE)

Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ:FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device companies develop and bring their products to market through clinical trials and support services.

Fortrea reported revenues of $697 million, down 1.8% year on year, falling short of analysts’ expectations by 0.9%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations.

Fortrea delivered the weakest full-year guidance update in the group. As expected, the stock is down 35.6% since the results and currently trades at $8.92.

Read our full analysis of Fortrea’s results here.

Repligen (NASDAQ:RGEN)

With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ:RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.

Repligen reported revenues of $167.5 million, flat year on year. This number met analysts’ expectations. Overall, it was a satisfactory quarter as it also logged an impressive beat of analysts’ organic revenue estimates.

Repligen pulled off the highest full-year guidance raise among its peers. The stock is flat since reporting and currently trades at $150.20.

Read our full, actionable report on Repligen here, it’s free.

Mettler-Toledo (NYSE:MTD)

With roots dating back to the precision balance innovations of Swiss engineer Erhard Mettler, Mettler-Toledo (NYSE:MTD) manufactures precision weighing instruments, analytical equipment, and product inspection systems used in laboratories, industrial settings, and food retail.

Mettler-Toledo reported revenues of $1.05 billion, up 11.8% year on year. This print topped analysts’ expectations by 3.6%. It was a very strong quarter as it also recorded a solid beat of analysts’ organic revenue estimates and a narrow beat of analysts’ full-year EPS guidance estimates.

The stock is down 9.3% since reporting and currently trades at $1,227.

Read our full, actionable report on Mettler-Toledo here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Join Paid Stock Investor Research

Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.